Skip to main content
. 2022 Mar 21;2(2):oeac019. doi: 10.1093/ehjopen/oeac019

Figure 3.

Figure 3

Major bleeding in P2Y12 inhibitor monotherapy versus aspirin monotherapy. The primary safety outcome of interest was major bleeding was evaluated using the DerSimonian and Laird random-effects model. There was no significant difference in the risk of major bleeding between P2Y12 inhibitor and aspirin monotherapy (RR 0.94 [95% CI 0.72–1.22], I2 = 42.6%). CI = confidence interval, MB = major bleeding, P2Y12i = P2Y12 inhibitor, RR = risk ratio.